

1614
PTO/SB/21 (01-03)Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number 10/600,303

Filing Date June 20, 2003

First Named Inventor Frank Wu

Art Unit 1614

Examiner Name TBD

Attorney Docket Number ENP-063

Total Number of Pages in This Submission

3

ENCLOSURES (Check all that apply)

- ☐ Fee Transmittal Form
☐ Fee Attached
☐ Amendment/Reply
☐ After Final
☐ Affidavits/declaration(s)
☐ Extension of Time Request
☐ Express Abandonment Request
☒ Information Disclosure Statement
☐ Certified Copy of Priority Document(s)
☐ Response to Missing Parts/
Incomplete Application
☐ Response to Missing Parts
under 37 CFR 1.52 or 1.53

- ☐ Drawing(s)
☐ Licensing-related Papers
☐ Petition
Petition to Convert to a
Provisional Application
Power of Attorney, Revocation
Change of Correspondence Address
☐ Terminal Disclaimer
☐ Request for Refund
☐ CD, Number of CD(s) _____

- ☐ After Allowance Communication
to Group
☐ Appeal Communication to Board
of Appeals and Interferences
Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)
☐ Proprietary Information
☐ Status Letter
☒ Other Enclosure(s) (please
Identify below):
Return Receipt Postcard
13 Referenced Publications

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual
Signature
Date

Jason D. Ferrone
Reg. No. 52,887
9/23/2003**CERTIFICATE OF TRANSMISSION/MAILING**I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA on this date: Sept. 23 2003

Typed or printed Stacie S. Capotosto

Signature

Date

9/23/03

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Or et al. Art Unit : 1614
Serial No. : 10/600,303 Examiner : TBD
Filed : June 20, 2003
Title : Cyclosporin Derivatives for the Treatment of Immune Disorders

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

The Information Disclosure Statement (form 1449) submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

In addition to those references cited in the USPTO-1449 form submitted herewith, Applicants would like to bring to the Examiner's attention copending, commonly-assigned patent application numbers:

- a. 09/800,856 (filed March 5, 2001);
- b. 09/976,219 (filed October 12, 2001);
- c. 09/975,923 (filed October 12, 2001);
- d. 10/309,934 (filed December 4, 2002); and
- e. 10/360,894 (filed February 7, 2003).

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Alexandria, VA 22313.

SEPT. 23, 2003

Date of Deposit

Date of Deposit _____
Stain S. Capotosto
 Signature _____

Signature _____

Stacie S. CAPOTOSTO

Typed or Printed Name of Person Signing Certificate

Applicant : Or et al.
Serial No. : 10/600,303
Filed : June 20, 2002
Page : Page 2 of 2


Attorney's Docket No.: ENP-063

No fee is believed to be due. In the event that a fee is due please charge Enanta
Pharmaceuticals, Inc., Deposit Account No. 50-2010, referencing Attorney Docket No. ENP-063.

Respectfully submitted,

Date: _____

9/23/2003



Jason D. Ferrone
Reg. No. 52,887

Enanta Pharmaceuticals, Inc.
Attn: Patent Dept.
500 Arsenal Street
Watertown, MA 02472

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (Rev. 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT Use several sheets if necessary				ATTY. DOCKET NO. ENP-063		SERIAL NO. 10/600,303	
				APPLICANT Frank Wu, et al.			
				FILING DATE June 20, 2003		GROUP 1614	

O I P E
 SEP 25 2003
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
AA	4,554,351	11/19/1985	Wenger et al.	544	177	5/5/1983	
AB	4,798,823	1/17/1989	Witzel et al.	514	11	6/3/1987	
AC	5,239,057	8/24/1993	Wang et al.	530	321	10/15/1991	
AD	5,427,960	6/27/1995	Wang et al.	436	536	10/5/1994	
AE	5,643,870	7/1/1997	Boelsterli et al.	514	11	2/26/1993	
AF	5,827,706	10/27/1998	Leitner et al.	435	183	6/6/1995	
AG	6,605,593 B1	8/12/2003	Naicker et al.	514	11	8/14/2000	
AH	2002/0132763	9/19/2002	Naicker et al.	514	11	11/7/2001	

FOREIGN PATENT DOCUMENTS								
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
					YES	NO		
BA WO 02/96122	12/21/1988	PCT	C07K	7/64				
BB WO 99/18120	4/15/1999	PCT	C07K	7/64				
BC WO 99/65933	12/23/1999	PCT	C07K	7/64				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
CA		Billich et al.; Enzymatic Synthesis of CsA, J. Biol. Chem., 262, 17258-17259 (1987).
CB		Faulds et al., Cyclosporin A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Immunoregulatory Disorders, Drugs 45(6), 953-1040;

EXAMINER	DATE CONSIDERED